Jasper Dingemanse

9.4k total citations
352 papers, 7.3k citations indexed

About

Jasper Dingemanse is a scholar working on Physiology, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Jasper Dingemanse has authored 352 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Physiology, 73 papers in Cardiology and Cardiovascular Medicine and 71 papers in Molecular Biology. Recurrent topics in Jasper Dingemanse's work include Sleep and Wakefulness Research (59 papers), Sleep and related disorders (53 papers) and Nitric Oxide and Endothelin Effects (48 papers). Jasper Dingemanse is often cited by papers focused on Sleep and Wakefulness Research (59 papers), Sleep and related disorders (53 papers) and Nitric Oxide and Endothelin Effects (48 papers). Jasper Dingemanse collaborates with scholars based in Switzerland, Netherlands and Germany. Jasper Dingemanse's co-authors include Paul L. M. van Giersbergen, Patricia N. Sidharta, Andreas Krause, Atef Halabi, Petra Hoever, Shirin Bruderer, Meindert Danhof, Clemens Muehlan, Mike Ufer and Alexander Treiber and has published in prestigious journals such as Nature Medicine, SHILAP Revista de lepidopterología and Hepatology.

In The Last Decade

Jasper Dingemanse

346 papers receiving 7.1k citations

Peers

Countries citing papers authored by Jasper Dingemanse

Since Specialization

Citations

This map shows the geographic impact of Jasper Dingemanse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jasper Dingemanse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jasper Dingemanse more than expected).

Fields of papers citing papers by Jasper Dingemanse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jasper Dingemanse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jasper Dingemanse. The network helps show where Jasper Dingemanse may publish in the future.

Co-authorship network of co-authors of Jasper Dingemanse

This figure shows the co-authorship network connecting the top 25 collaborators of Jasper Dingemanse. A scholar is included among the top collaborators of Jasper Dingemanse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jasper Dingemanse. Jasper Dingemanse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension 2024 ·Journal of Pharmacokinetics and Pharmacodynamics ·Janneke M. Brussee, Patricia N. Sidharta, Jasper Dingemanse, Andreas Krause	1
2	Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo 2023 ·Clinical and Translational Science ·(unknown), Jasper Dingemanse, Stéphane Delahaye, Luboš Janů, John van den Anker, Benjamin Berger, Priska Kaufmann	2
3	Pharmacokinetics, pharmacodynamics and safety of the novel C‐X‐C chemokine receptor 3 antagonist ACT‐777991: Results from the first‐in‐human study in healthy adults 2023 ·British Journal of Clinical Pharmacology ·(unknown), Martine Géhin, (unknown), (unknown), (unknown), Daniel S. Strasser, Jasper Dingemanse	6
4	Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a₁ receptor) antagonist 2023 ·Pharmacology Research & Perspectives ·(unknown), (unknown), Andreas Krause, Marc Pfister, John van den Anker, Jasper Dingemanse, Priska Kaufmann	2
5	The orexin story and orexin receptor antagonists for the treatment of insomnia 2023 ·Journal of Sleep Research ·Clemens Muehlan, Catherine Roch, (unknown), Jasper Dingemanse	46
6	Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists 2023 ·Biomolecules ·(unknown), Jasper Dingemanse, (unknown), (unknown), Martine Géhin, Andreas Krause	1
7	Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist 2022 ·CPT Pharmacometrics & Systems Pharmacology ·Andreas Krause, (unknown), Janneke M. Brussee, Clemens Muehlan, Jasper Dingemanse	8
8	A Multipurpose First‐in‐Human Study With the Novel CXCR7 Antagonist ACT‐1004‐1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker 2021 ·Clinical Pharmacology & Therapeutics ·Christine Huynh, (unknown), Daniel S. Strasser, (unknown), Mohamed Al‐Ibrahim, Henriette E. Meyer zu Schwabedissen, Jasper Dingemanse, Mike Ufer	9
9	PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT 2021 ·Journal of Pharmacokinetics and Pharmacodynamics ·(unknown), Pierre‐Éric Juif, Jasper Dingemanse, Andreas Krause	5
10	Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development 2020 ·Scientific Reports ·(unknown), Matthias Rottmann, Sergio Wittlin, Nathalie Gobeau, Andreas Krause, Jasper Dingemanse, Jörg J. Möhrle, Melissa A. Penny	10
11	Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects 2020 ·Biomedicine & Pharmacotherapy ·Jasper Dingemanse, Pascal Charef, Jed Black, (unknown)	0
12	Modelling pharmacokinetics and pharmacodynamics of the selective S1P₁ receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients 2019 ·British Journal of Clinical Pharmacology ·(unknown), Pierre‐Éric Juif, Jasper Dingemanse, Andreas Krause	4
13	Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension 2017 ·Expert Opinion on Drug Safety ·Shirin Bruderer, (unknown), (unknown), Jasper Dingemanse	7
14	Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement 2017 ·Clinical Pharmacology & Therapeutics ·(unknown), Daniel Oder, Peter Nordbeck, Christian Zwingelstein, Olivier Morand, Richard W.D. Welford, Jasper Dingemanse, Christoph Wanner	87
15	<b>Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Macitentan, a New Endothelin Receptor Antagonist, in Healthy Japanese Male Subjects </b> 2016 ·Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics ·(unknown), Jasper Dingemanse, (unknown), Hiroyuki Fukase	1
16	Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment 2013 ·The Journal of Clinical Pharmacology ·Patricia N. Sidharta, Nicolas Lindegger, (unknown), Jasper Dingemanse	29
17	Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple‐dose study in healthy subjects 2013 ·The Journal of Clinical Pharmacology ·Patricia N. Sidharta, Paul L. M. van Giersbergen, Jasper Dingemanse	64
18	PHARMACOKINETICS AND TOLERABILITY OF THE ORAL SELECTIVE PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG AFTER MULTIPLE-DOSE ADMINISTRATION IN HEALTHY MALE SUBJECTS 2011 ·Clinical Pharmacology & Therapeutics ·(unknown), Jasper Dingemanse, (unknown), Patricia N. Sidharta, (unknown), Priska Kaufmann	1
19	Acute Hemodynamic Effects of Single‐Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS‐1 Study 2009 ·The Journal of Clinical Pharmacology ·Ekkehard Gruenig, Evangelos D. Michelakis, Jean‐Luc Vachiéry, Carmine Dario Vizza, F. Joachim Meyer, Martin Doelberg, Doris Bach, Jasper Dingemanse, Nazzareno Galiè	49
20	Altered pharmacokinetic-pharmacodynamic relationship of heptabarbital in experimental renal failure in rats. 1988 ·Journal of Pharmacology and Experimental Therapeutics ·Jasper Dingemanse, Martine Polhuijs, Meindert Danhof	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact